# Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

> **NCT03537521** · — · WITHDRAWN · sponsor: **Cardioangiologisches Centrum Bethanien**

## Conditions studied

- Severe Bleeding
- Urgent Surgery

## Interventions

- **PROCEDURE:** Urgent surgery which can not be postponed to the next 24 hrs

## Key facts

- **NCT ID:** NCT03537521
- **Lead sponsor:** Cardioangiologisches Centrum Bethanien
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04
- **Primary completion:** 2022-04
- **Final completion:** 2023-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** due to corona pandemic crisis
- **Last updated:** 2020-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537521, "Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03537521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*